Related Experiment Video
Updated: Apr 27, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Infection in severe asthma exacerbations and critical asthma syndrome
Christian E Sandrock1, Andrew Norris
1Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, Davis, School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA, 95817, USA, cesandrock@ucdavis.edu.
Abstract:
In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma syndrome. During severe acute exacerbations, infectious agents must be treated empirically, but the initial treatment regimens can vary and viral coverage may also vary based on seasonality and patient age. Early treatment with ceftriaxone and azithromycin, along with oseltamivir in winter months, should be initiated with all cases of severe exacerbations where infection is suspected, and definitely in critical asthma syndrome until infection is excluded by appropriate diagnostic testing. In this manuscript we will outline the impact of the major viral agents on severe asthma including the data from the 2009 H1N1 influenza pandemic. The role of bacterial infections in acute exacerbations of asthma will also be reviewed as well as the benefit of empiric antibiotics and the role of macrolides in both acute and chronic asthma.
Insights
Infectious agents, especially viruses like rhinovirus and influenza, are key triggers for severe asthma exacerbations. Early empirical treatment with antibiotics and antivirals is crucial for managing these critical events.
Area of Science:
- * Pulmonology and Infectious Diseases
- * Respiratory Medicine
- * Clinical Immunology
Background:
- * Infectious agents are primary drivers of chronic persistent asthma and severe acute exacerbations of bronchial asthma (AEBA).
- * Viral infections, including human rhinovirus-C, respiratory syncytial virus, and influenza A, are prevalent threats in AEBA, particularly near-fatal and fatal cases.
- * Bacterial infections and co-infections can also contribute to disease severity and poorer outcomes in hospitalized patients, increasing the risk of critical asthma syndrome.
Purpose of the Study:
- * To review the impact of major viral agents on severe asthma, including insights from the 2009 H1N1 influenza pandemic.
- * To examine the role of bacterial infections in AEBA.
- * To discuss the benefits of empiric antibiotic therapy and the utility of macrolides in managing both acute and chronic asthma.
Main Methods:
- * Literature review and synthesis of existing data on infectious triggers in asthma exacerbations.
- * Analysis of clinical outcomes related to specific viral and bacterial pathogens.
- * Evaluation of current treatment guidelines for empirical antimicrobial therapy in severe asthma.
Main Results:
- * Viral agents are identified as predominant triggers in severe asthma exacerbations.
- * Co-infections can worsen prognosis in hospitalized patients, leading to critical asthma syndrome.
- * Empirical treatment strategies, including antibiotics (ceftriaxone, azithromycin) and antivirals (oseltamivir), are recommended for suspected infections in severe AEBA.
Conclusions:
- * Prompt empirical treatment of suspected infections is vital in managing severe asthma exacerbations, especially in cases of critical asthma syndrome.
- * Understanding the specific roles of viral and bacterial pathogens informs optimal therapeutic approaches.
- * Further research into the efficacy of macrolides in asthma management is warranted.
Related Concept Videos
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma I: Introduction
Asthma III: Clinical Manifestations
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Asthma-I: Introduction

